Epigenetic markers and response to chemotherapy in cancer

Disease Markers

Volumn 23, Issue 1-2, 2007, Pages 43-49

  Strathdee, Gordon ^a  

^a UNIVERSITY OF GLASGOW   (United Kingdom)

Author keywords

Chemotherapy; DNA methylation; Drug resistance; Epigenetics

Indexed keywords

ALKYLATING AGENT; ANTINEOPLASTIC AGENT; DOXORUBICIN; FANCONI ANEMIA GROUP F PROTEIN; FLUOROURACIL; GENOMIC DNA; GLYCOPROTEIN P; METHYLATED DNA PROTEIN CYSTEINE METHYLTRANSFERASE; MULTIDRUG RESISTANCE PROTEIN 1; PROTEIN MLH1; PROTEIN P53; PROTEIN P73; TUMOR MARKER;

CANCER CELL CULTURE; CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER RESEARCH; CANCER SURVIVAL; CHEMOSENSITIVITY; COLORECTAL CANCER; CPG ISLAND; DISEASE MARKER; DNA DAMAGE; DNA DETERMINATION; DNA METHYLATION; DNA REPLICATION; DRUG RESPONSE; DRUG SENSITIVITY; ENDOMETRIUM CANCER; EPIGENETICS; GENE EXPRESSION; GENE TECHNOLOGY; GENETIC ASSOCIATION; HUMAN; MELANOMA; MISMATCH REPAIR; OVARY CANCER; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROGNOSIS; QUALITATIVE ANALYSIS; QUANTITATIVE ANALYSIS; REVIEW; TREATMENT RESPONSE;

EID: 33847347345     PISSN: 02780240     EISSN: None     Source Type: Journal    
DOI: 10.1155/2007/610815     Document Type: Review

References (39)

1. T. Ando, M. Nishimura and Y. Oka, Decitabine (5-Aza-2′- deoxycytidine) decreased DNA methylation and expression of MDR-1 gene in K562/ADM cells, Leukemia 11 (2000), 1915-1920.
2. C. N. Arnold, A. Goel and C.R. Boland, Role of hMLH1 promoter hypermethylation in drug resistance to 5-fluorouracil in colorectal cancer cell lines, Int J Cancer 106 (2003), 66-73.
3. S.A. Belinsky, K.J. Nikula, W.A. Palmisano, R. Michels, G. Saccomanno, E. Gabrielson, S.B. Baylin and J.G. Herman, Aberrant methylation of p16(ink4a) is an early event in lung cancer and a potential biomarker for early diagnosis, Proc Natl Acad Sci USA 20 (1998), 11891-11896.
4. S.L. Berger, Histone modifications in transcriptional regulation, Curr Opin Genet Dev 2 (2002), 142-148.
5. A. Bird, The Relationship of DNA Methylation to Cancer, Cancer Surveys (1996), 87-101.
6. J. Costello, F and C. Plass, Methylation matters, J Med Genet (2001), 285-303.
7. J.F. Costello, M.C. Fruhwald, D.J. Smiraglia, L.J. Rush, G.P. Robertson, X. Gao, F.A. Wright, J.D. Feramisco, P. Peltomaki, J.C. Lang, D.E. Schuller, L. Yu, C.D. Bloomfield, M.A. Caligiuri, A. Yates, R. Nishikawa, H.S. Huang, N.J. Petrelli, X. Zhang, M.S. O'Dorisio, W.A. Held, W. Cavenee and C. Plass, Aberrant CpG-island methylation has non-random and tumour-type-specific patterns, Nat Genet (2000), 132-138.
8. J.M. Cunningham, E.R. Christensen, D.J. Tester, C.Y. Kim, P.C. Roche, L.J. Burgart and S.N. Thibodeau, Hypermethylation of the hMLH1 promoter in colon cancer with microsatellite instability, Cancer Res 15 (1998), 3455-3460.
9. C. Dahl and P. Guldberg, DNA methylation analysis techniques, Biogerontology 4 (2003), 233-250.
10. C.A. Eads, K.D. Danenberg, K. Kawakami, L.B. Saltz, C. Blake, D. Shibata, P.V. Danenberg and P.W. Laird, Methy-Light: a high-throughput assay to measure DNA methylation, Nuc Acid Res 8 (2000), E32.
11. M. Esteller, G. Gaidano, S.N. Goodman, V. Zagonel, D. Capello, B. Botto, D. Rossi, A. Gloghini, U. Vitolo, A. Carbone, S.B. Baylin and J.G. Herman, Hypermethylation of the DNA repair gene O(6)-methylguanine DNA methyltransferase and survival of patients with diffuse large B-cell lymphoma, J Natl Cancer Inst 1 (2002), 26-32.
12. M. Esteller, J. Garcia-Foncillas, E. Andion, S.N. Goodman, O.F. Hidalgo, V. Vanaclocha, S.B. Baylin and J.G. Herman, Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents, N Engl J Med 19 (2000), 1408-1409.
13. M. Esteller and J.G. Herman, Generating mutations but providing chemosensitivity: the role of O6-methylguanine DNA methyltransferase in human cancer, Oncogene 1 (2004), 1-8.
14. M. Esteller, M. Sanchez-Cespedes, R. Rosell, D. Sidransky, S.B. Baylin and J.G. Herman, Detection of aberrant promoter hypermethylation of tumour suppressor genes in serum DNA from non-small cell lung cancer patients, Cancer Res (1999), 67-70.
15. D. Fink, S. Aebi and S.B. Howell, The role of DNA mismatch repair in drug resistance, Clin Cancer Res (1998), 1-6.
16. M. Frommer, L.E. McDonald, D.S. Millar, C.M. Collis, F. Watt, G.W. Grigg, P.L. Molloy and C.L. Paul, A genomic sequencing protocol that yields a positive display of 5-methylcytosine residues in individual DNA strands, Proc Natl Acad Sci USA 5 (1992), 1827-1831.
17. K.B. Fryxell, S.B. McGee, D.K. Simoneaux, C.L. Willman and M.M. Cornwell, Methylation analysis of the human multidrug resistance 1 gene in normal and leukemic hematopoietic cells, Leukemia 6 (1999), 910-917.
18. S. Fulda, M.U. Kufer, E. Meyer, F. van Valen, B. Dockhorn-Dworniczak and K.M. Debatin, Sensitization for death receptor- or drug-induced apoptosis by re-expression of caspase-8 through demethylation or gene transfer, Oncogene 41 (2001), 5865-5877.
19. G. Gifford, J. Paul, P.A. Vasey, S.B. Kaye and R. Brown, The acquisition of hMLH1 methylation in plasma DNA after chemotherapy predicts poor survival for ovarian cancer patients, Clin Cancer Res 13 (2004), 4420-4426.
20. C. Goessl, H. Krause, M. Muller, R. Heicappell, M. Schrader, J. Sachsinger and K. Miller, Fluorescent methylation-specific polymerase chain reaction for DNA-based detection of prostate cancer in bodily fluids, Cancer Res 21 (2000), 5941-5945.
21. M.E. Hegi, A.C. Diserens, S. Godard, P.Y. Dietrich, L. Regli, S. Ostermann, P. Otten, G. Van Melle, N. de Tribolet and R. Stupp, Clinical trial substantiates the predictive value of O-6-methylguanine-DNA methyltransferase promoter methylation in glioblastoma patients treated with temozolomide, Clin Cancer Res 6 (2004), 1871-1874.
22. J.G. Herman, J.R. Graff, S. Myohanen, B.D. Nelkin and S.B. Baylin, Methylation-specific PCR: A novel PCR assay for methylation status of CpG islands, Proc Natl Acad Sci USA (1996), 9821-9826.
23. P. Kantharidis, S. El-Osta, M. Silva, G. Lee, X.F. Hu and J. Zalcberg, Regulation of MDR1 gene expression: emerging concepts, Drug Resist Updat 2 (2000), 99-108.
24. G.M. Li, The role of mismatch repair in DNA damage-induced apoptosis, Oncol Res 9 (1999), 393-400.
25. T. Ohtsuka, X.F. Liu, Y. Koga, Y. Kitajima, Y. Nakafusa, C.W. Ha, S.W. Lee and K. Miyazaki, Methylation-induced silencing of ASC and the effect of expressed ASC on p53-mediated chemosensitivity in colorectal cancer, Oncogene (2005).
26. C. Pingoud-Meier, D. Lang, A.J. Janss, L.B. Rorke, P.C. Phillips, T. Shalaby and M.A. Grotzer, Loss of caspase-8 protein expression correlates with unfavorable survival outcome in childhood medulloblastoma, Clin Cancer Res 17 (2003), 6401-6409.
27. J.A. Plumb, G. Strathdee, J. Sludden, S.B. Kaye and R. Brown, Reversal of drug resistance in human tumour xenografts by 2′deoxy-5-azacytidine- induced demethylation of the hMLH1 gene promoter, Cancer Res (2000), 6039-6044.
28. C.M. Ribic, D.J. Sargent, M.J. Moore, S.N. Thibodeau, A.J. French, R.M. Goldberg, S.R. Hamilton, P. Laurent-Puig, R. Gryfe, L.E. Shepherd, D. Tu, M. Redston and S. Gallinger, Tumor microsatellite-instability status as a predictor of benefit from fluorouracil-based adjuvant chemotherapy for colon cancer, N Engl J Med 3 (2003), 247-257.
29. V. Shridhar, B. K.C., J. Staub, R. Avula, Y.K. Lee, K. Kalli, H. Huang, L.C. Hartmann, S.H. Kaufmann and D.I. Smith, Loss of Expression of a New Member of the DNAJ Protein Family Confers Resistance to Chemotherapeutic Agents Used in the Treatment of Ovarian Cancer, Cancer Res (2001), 4258-4265.
30. M.S. Soengas, R.M. Alarcon, H. Yoshida, A.J. Giaccia, R. Hakem, T.W. Mak and S.W. Lowe, Apaf-1 and caspase-9 in p53-dependent apoptosis and tumor inhibition, Science 5411 (1999), 156-159.
31. M.S. Soengas, P. Capodieci, D. Polsky, J. Mora, M. Esteller, X. Opitz-Araya, R. McCombie, J.G. Herman, W.L. Gerald, Y.A. Lazebnik, C. Cordon-Cardo and S.W. Lowe, Inactivation of the apoptosis effector Apaf-1 in malignant melanoma, Nature 6817 (2001), 207-211.
32. G. Strathdee, M. MacKean, M. Illand and R. Brown, A role for methylation of the hMLH1 promoter in loss of hMLH1 expression and drug resistance in ovarian cancer, Oncogene (1999), 2335-2341.
33. G. Strathdee, J.K. Vass, K.A. Oien, N. Siddiqui, J. Curto-Garcia and R. Brown, Demethylation of the MCJ gene in stage III/IV epithelial ovarian cancer and response to chemotherapy, Gynecol Oncol 3 (2005), 898-903.
34. T. Taniguchi, M. Tischkowitz, N. Ameziane, S.V. Hodgson, C.G. Mathew, H. Joenje, S.C. Mok and A.D. D'Andrea, Disruption of the Fanconi anemia-BRCA pathway in cisplatinsensitive ovarian tumors, Nat Med 5 (2003), 568-574.
35. J.M. Teodoridis, J. Hall, S. Marsh, H.D. Kannall, C. Smyth, J. Curto, N. Siddiqui, H. Gabra, H.L. McLeod, G. Strathdee and R. Brown, CpG island methylation of DNA damage response genes in advanced ovarian cancer, Cancer Res 19 (2005), 8961-8967.
36. G.S. Watts, R.O. Pieper, J.F. Costello, Y.M. Peng, W.S. Dalton and B.W. Futscher, Methylation of discrete regions of the O6-methylguanine DNA methyltransferase (MGMT) CpG island is associated with heterochromatinization of the MGMT transcription start site and silencing of the gene, Mol Cell Biol 9 (1997), 5612-5619.
37. M.Weber, J.J. Davies, D.Wittig, E.J. Oakeley, M. Haase,W.L. Lam and D. Schubeler, Chromosome-wide and promoterspecific analyses identify sites of differential DNA methylation in normal and transformed human cells, Nat Genet 8 (2005), 853-862.
38. S.H. Wei, C.M. Chen, G. Strathdee, J. Harnsomburana, C.R. Shyu, F. Rahmatpanah, H. Shi, S.W. Ng, P.S. Yan, K.P. Nephew, R. Brown and T.H. Huang, Methylation microarray analysis of late-stage ovarian carcinomas distinguishes progression-free survival in patients and identifies candidate epigenetic markers, Clin Cancer Res 7 (2002), 2246-2252.
39. Z. Xiong and P.W. Laird, COBRA: a sensitive and quantitative DNA methylation assay, Nuc Acid Res (1997), 2532-2534.